BACKGROUND: @entity1397 is a prodrug, the minority of which is converted to an active metabolite by hepatic cytochrome P450 ( @entity4433 ), however, most of it is metabolized to inactive substance by hepatic @entity2601 ( @entity2601 ). Meanwhile angiotensin-converting enzyme inhibitors (ACEIs) are mostly metabolized by @entity2601 . We aimed to assess the impact of ACEIs on platelet inhibition by @entity1397 . METHODS: We genotyped variants @entity2601 , @entity4433 *2 and *3 in 502 @entity1 with @entity1187 ( @entity1187 ) receiving @entity1397 therapy, and analyzed the effects of ACEIs on responsiveness to @entity1397 by the @entity19319 ( @entity19319 ) phosphorylation assay and @entity857 -stimulated impedance whole blood platelet aggregation assay. RESULTS: It showed that the allele frequency of @entity2601 c.428A was 0% in these @entity1 . 45.22% (227/502) of these @entity1 were carriers of @entity4433 *2 or @entity5060 *3 loss-of-function alleles. Among them, 57.71% (131/227) of the @entity1 with @entity4433 variants received ACEIs therapy. In a total of 502 @entity1 , there was no difference in the @entity19319 or the impedance whole blood platelet aggregation assay between the ACEIs group and non-ACEIs group [56.26    14.55% versus 57.76    13.56%, p = 0.241; 0 (0 - 2)     vs. 0 (0 - 2)    , p = 0.856]. In the @entity4433 variant @entity1 , there was no difference in the @entity19319 or the impedance whole blood platelet aggregation assay between ACEIs group and non-ACEIs group [57.24    15.12% versus 58.07    13.90%, p = 0.667; 0 (0 - 2)     versus 0 (0 - 2)    , p = 0.536]. In the subgroups of @entity1187 @entity1 ( @entity1459 , non-ST-segment elevation @entity583 , ST-segment elevation @entity583 ), there was no difference in the @entity19319 -PRI between the ACEIs group and non-ACEIs group [55.81    15.24% versus 58.37    13.31%, p = 0.103; 55.76    15.20% versus 49.09    15.22%, p = 0.098; 58.13    11.48% versus 61.87    10.34%, p = 0.221], and there was no difference in the impedance whole blood platelet aggregation assay between ACEIs group and non-ACEIs group [0 (0 - 2)     versus 0 (0 - 2)    , p = 0.936; 0 (0 - 2)     versus 0 (0 - 2)    , p = 0.625; 0 (0 - 1.25)     versus 0 (0 - 1.5)    , p = 0.788]. CONCLUSIONS: In our study, when ACEIs were used with @entity1397 , platelet response to @entity1397 was not affected. These findings suggest that the drug interaction between @entity1397 and ACEI is of little relevance in platelet function.

Angiotensin-Converting Enzyme Inhibitors' Influence on Antiplatelet Therapy of @entity1397 in XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1187 :: ('MESH:D054058', 'Disease') :: ['ACS', 'acute coronary syndrome'] @entity2601 :: ('1066', 'Gene') :: ['carboxylesterase1', 'CES1'] @entity4433 :: ('1557', 'Gene') :: ['CYP2C19'] @entity1397 :: ('MESH:C055162', 'Chemical') :: ['Clopidogrel', 'clopidogrel'] @entity1459 :: ('MESH:D000789', 'Disease') :: ['unstable angina'] @entity5060 :: ('1559', 'Gene') :: ['CYP2C9'] @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction'] @entity857 :: ('MESH:D000244', 'Chemical') :: ['ADP'] @entity19319 :: ('7408', 'Gene') :: ['VASP-PRI', 'VASP', 'vasodilator-stimulated phosphoprotein']
@entity1187 :: (MESH:D054058,Disease) :: ['ACS']
